Reviva Pharmaceuticals - CW23 | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.13 21:30
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.06.

EBIT: As of FY2025 Q3, the actual value is USD -4.086 M.

Financial Metrics by Segment

Segment Revenue

  • The company did not report any revenue from product sales as it is a clinical-stage biopharmaceutical company focused on research and development.

Operational Metrics

  • Net Loss: The net loss for the three months ended September 30, 2025, was approximately $4.0 million, compared to $8.4 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was approximately $16.5 million, compared to $23.7 million in 2024.
  • Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were approximately $2.1 million, a decrease from $6.9 million in the same period in 2024. For the nine months ended September 30, 2025, these expenses were approximately $10.0 million, down from $18.2 million in 2024.
  • General and Administrative Expenses: These expenses were approximately $1.9 million for the three months ended September 30, 2025, compared to $1.6 million in 2024. For the nine months ended September 30, 2025, the expenses were approximately $6.7 million, compared to $6.3 million in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was approximately $18.8 million, compared to $24.4 million in 2024.
  • Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was approximately $18.5 million, compared to $6.6 million in 2024.

Unique Metrics

  • Warrant Liabilities: The company recognized a remeasurement of warrant liabilities loss of approximately $27.8 thousand for the three months ended September 30, 2025, compared to a gain of $72.3 thousand in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company plans to complete the clinical development of its lead drug candidate, brilaroxazine, for the treatment of acute and maintenance schizophrenia. A meeting with the FDA is planned for Q4-2025 to discuss the submission of an NDA based on existing data, with a target submission in Q2-2026 if the FDA response is positive.
  • Non-Core Business: The company may continue the clinical development of brilaroxazine for other indications such as bipolar disorder, major depressive disorder, and others, subject to additional financing. Additionally, the development of a second drug candidate, RP1208, for depression and obesity may be advanced, contingent on financing.
  • Priority: The company emphasizes the completion of the clinical development of brilaroxazine and the potential NDA submission as its primary strategic focus.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.